Reports say PAHO revoked U.S. measles elimination status; elebsiran-tobevibart meets hepatitis delta goal; doxycycline tied to pregnancy loss

Listen to this post
read by AI voices · all episodesThe Pan American Health Organization (PAHO) has revoked U.S. measles elimination status, according to a Wall Street Journal report cited by Reuters on Nov. 13, as confirmed U.S. cases reached 5,412 for 2026.
Vir Biotechnology said its hepatitis delta combination met the primary end point in a phase 3 trial, and a cohort study tied early-pregnancy doxycycline to higher pregnancy loss.
- Public health Nov 13, 2026The Pan American Health Organization (PAHO) has revoked the measles elimination status of the United States, according to a Wall Street Journal report cited by Reuters on Nov. 13, Contagion Live reported; PAHO did not immediately respond to a request for comment on the report. Reuters had reported Nov. 11 that the determination was expected to be made public early the following week. The Centers for Disease Control and Prevention (CDC) reported 5,412 confirmed cases in 2026 as of Nov. 12; its website lists six deaths, while state health departments have reported 10, according to Contagion Live.
- Research Nov 8, 2026Vir Biotechnology said 44% of patients given monthly subcutaneous elebsiran and tobevibart achieved undetectable hepatitis delta virus RNA with alanine aminotransferase normalization at week 48, the primary end point, versus 0% in the delayed-treatment group at week 12 (P < .0001), in the 124-patient phase 3 trial randomized 2:1. Undetectable virus at week 48, a key secondary end point, was reached by 79%. The topline results were presented in a late-breaking oral session at The Liver Meeting 2026, HCPLive reported Nov. 8, and Vir said it plans a U.S. filing in mid-2027.
- Research Nov 10, 2026In an active-comparator claims cohort published Nov. 10 in the Annals of Internal Medicine, doxycycline for respiratory tract infection in early pregnancy was associated with higher risk of pregnancy loss than amoxicillin (adjusted relative risk 1.54, 95% CI 1.41 to 1.68, in MarketScan and 1.40, 95% CI 1.28 to 1.53, in Medicaid) and than macrolides (1.39 and 1.36). For acne, the association versus topical clindamycin was significant in MarketScan (1.49, 95% CI 1.26 to 1.76) but not in Medicaid (1.03, 95% CI 0.80 to 1.33). The study is observational.Source: Annals of Internal Medicine
- Research Nov 12, 2026In a national prescription-data cohort published Nov. 12 in Clinical Infectious Diseases, women were less likely to abandon long-acting cabotegravir PrEP than daily oral PrEP (11.9% versus 18.1%, adjusted relative risk 0.68, 95% CI 0.62 to 0.74), while men were more likely to (10.2% versus 8.1%, adjusted relative risk 1.25, 95% CI 1.20 to 1.31). The study covered prescriptions from January 2022 to June 2025.Source: Clinical Infectious Diseases
The weekly innovation roundup for infectious disease, published every Sunday for the week before; every item links to its sources. Latest infectious disease news · All specialties